Form 4: Twist Bioscience CEO Sells Shares for Tax Obligations

Sentiment:

Insider Transaction Report 10 December 2025 4:05 PM

Twist Bioscience CEO Emily M. Leproust sold 2,255 shares of common stock at $32.878 per share to cover tax withholding obligations related to vested Restricted Stock Units.

Summary

Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (TWST), reported a sale of 2,255 shares of common stock.
The transaction is scheduled for December 8, 2025, at a price of $32.878 per share.
The sale is non-discretionary, executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units, as mandated by the company's equity incentive plans ('sell to cover' transaction).
Following this transaction, Ms. Leproust will directly beneficially own 875,918 shares of common stock.
The filing also details various employee stock options held by Ms. Leproust, including one for 64,950 shares that vested on December 19, 2022, upon meeting performance criteria.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's a sale of shares, it's explicitly for tax purposes and not a discretionary move, which is a common and expected event. The CEO retains a substantial stake, indicating continued alignment with shareholder interests.

Positives

The sale is non-discretionary, indicating it is not a voluntary decision by the CEO to reduce her stake due to a lack of confidence in the company.
The CEO continues to hold a significant number of shares (875,918) and various stock options, aligning her interests with shareholders.

Negatives

A reduction in direct beneficial ownership, even if for tax purposes, slightly decreases the CEO's direct stake in the company.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, as it primarily reports an insider transaction.

Industry Context

This insider transaction is a routine 'sell to cover' event for tax purposes, common across all industries for executives receiving equity compensation. It does not reflect specific industry trends or competitive positioning within the synthetic biology sector.

Comparison to Industry Standards

The 'sell to cover' transaction is a standard practice for executives across various industries, including biotechnology, to manage tax liabilities arising from equity compensation vesting.
It is not indicative of company-specific performance relative to peers like Ginkgo Bioworks or Codexis, but rather a common mechanism for executive compensation management.

Related Party Transactions

The transaction itself is a related party transaction as it involves the CEO and the company's equity incentive plan, but no other specific related party dealings are disclosed.

Stakeholder Impact

Shareholders: The sale is a routine tax-related transaction and does not signal a change in management's confidence. The CEO retains significant ownership, maintaining alignment of interests.
Employees: The transaction relates to the company's equity incentive plans, which are a common form of compensation for employees, including executives.

Next Steps

No specific future actions or milestones are mentioned in this Form 4 filing beyond the reporting of the transaction.

Key Dates

Date	Description
2016-09-01	25% of shares subject to an employee stock option (exercise price $5.95) vested, with 1/48th vesting monthly thereafter.
2017-09-28	10% of shares subject to an employee stock option (exercise price $8.82) vested.
2018-09-28	15% of shares subject to an employee stock option (exercise price $8.82) vested, with 1/48th vesting monthly thereafter.
2019-10-31	20% of shares subject to an employee stock option (exercise price $26.66) vested and became exercisable, with 1/60th vesting monthly thereafter.
2020-09-01	Grant date for performance stock options (exercise price $67.85).
2020-10-24	25% of shares subject to an employee stock option (exercise price $23.33) vested, with 1/48th vesting monthly thereafter.
2022-12-19	Performance stock options (exercise price $67.85) vested and became exercisable due to meeting applicable performance criteria.
2025-09-28	Expiration date for an employee stock option (exercise price $5.95).
2025-12-08	Date of common stock transaction (sale of 2,255 shares).
2025-12-10	Signature date of the reporting person's attorney-in-fact.
2027-09-28	Expiration date for an employee stock option (exercise price $8.82).
2028-11-18	Expiration date for an employee stock option (exercise price $26.66).
2029-10-23	Expiration date for an employee stock option (exercise price $23.33).
2030-08-31	Expiration date for an employee stock option (exercise price $67.85).

Recommendation

hold

This Form 4 filing reports a routine, non-discretionary 'sell to cover' transaction by the CEO for tax purposes. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The CEO maintains a substantial equity stake, which is generally a positive sign of alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial updates.

Keywords

Twist Bioscience, TWST, Emily M. Leproust, CEO, Director, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Equity Incentive Plan, Biotechnology, Synthetic Biology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.